News on Oculocerebrorenal_Syndrome from BioPortfolio.com http://www.BioPortfolio.com Consolidated Oculocerebrorenal_Syndrome news from BioPortfolio.com Wed, 10 Feb 2010 12:59:55 GMT en Research and Markets: Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041184&HITNO=0&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041184&THISHREF=http://c.moreover.com/click/here.pl%3fz2539024659%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041184&HITNO=0&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041184&THISHREF=http://c.moreover.com/click/here.pl%3fz2539024659%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire via Yahoo!: Research and Markets: Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041265&HITNO=1&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041265&THISHREF=http://c.moreover.com/click/here.pl%3fz2539053707%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041265&HITNO=1&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041265&THISHREF=http://c.moreover.com/click/here.pl%3fz2539053707%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: Research and Markets: Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041206&HITNO=2&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041206&THISHREF=http://c.moreover.com/click/here.pl%3fz2539033677%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041206&HITNO=2&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041206&THISHREF=http://c.moreover.com/click/here.pl%3fz2539033677%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsBlaze: Research and Markets: Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041249&HITNO=3&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041249&THISHREF=http://c.moreover.com/click/here.pl%3fz2539048511%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041249&HITNO=3&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041249&THISHREF=http://c.moreover.com/click/here.pl%3fz2539048511%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Research and Markets: Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041245&HITNO=4&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041245&THISHREF=http://c.moreover.com/click/here.pl%3fz2539047804%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041245&HITNO=4&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041245&THISHREF=http://c.moreover.com/click/here.pl%3fz2539047804%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 ...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039357&HITNO=5&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039357&THISHREF=http://c.moreover.com/click/here.pl%3fz2538057086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039357&HITNO=5&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039357&THISHREF=http://c.moreover.com/click/here.pl%3fz2538057086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: QR Pharma Initiates Clinical Trial for Cognitively Impaired Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041585&HITNO=6&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041585&THISHREF=http://c.moreover.com/click/here.pl%3fz2539174665%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041585&HITNO=6&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041585&THISHREF=http://c.moreover.com/click/here.pl%3fz2539174665%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: QR Pharma Initiates Clinical Trial for Cognitively Impaired Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041567&HITNO=7&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041567&THISHREF=http://c.moreover.com/click/here.pl%3fz2539170599%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041567&HITNO=7&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041567&THISHREF=http://c.moreover.com/click/here.pl%3fz2539170599%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: QR Pharma commences clinical trial of Posiphen in early stage AD patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041451&HITNO=8&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041451&THISHREF=http://c.moreover.com/click/here.pl%3fz2539121070%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041451&HITNO=8&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041451&THISHREF=http://c.moreover.com/click/here.pl%3fz2539121070%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: QR Pharma Initiates Clinical Trial for Cognitively Impaired Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041425&HITNO=9&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041425&THISHREF=http://c.moreover.com/click/here.pl%3fz2539107057%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041425&HITNO=9&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041425&THISHREF=http://c.moreover.com/click/here.pl%3fz2539107057%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: QR Pharma Initiates Clinical Trial for Cognitively Impaired Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041347&HITNO=10&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041347&THISHREF=http://c.moreover.com/click/here.pl%3fz2539079304%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041347&HITNO=10&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041347&THISHREF=http://c.moreover.com/click/here.pl%3fz2539079304%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: QR Pharma Initiates Clinical Trial for Cognitively Impaired Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041267&HITNO=11&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041267&THISHREF=http://c.moreover.com/click/here.pl%3fz2539054756%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041267&HITNO=11&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041267&THISHREF=http://c.moreover.com/click/here.pl%3fz2539054756%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: QR Pharma Initiates Clinical Trial for Cognitively Impaired Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041263&HITNO=12&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041263&THISHREF=http://c.moreover.com/click/here.pl%3fz2539053545%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041263&HITNO=12&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041263&THISHREF=http://c.moreover.com/click/here.pl%3fz2539053545%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: QR Pharma Initiates Clinical Trial for Cognitively Impaired Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041242&HITNO=13&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041242&THISHREF=http://c.moreover.com/click/here.pl%3fz2539046228%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041242&HITNO=13&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041242&THISHREF=http://c.moreover.com/click/here.pl%3fz2539046228%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: QR Pharma Initiates Clinical Trial for Cognitively Impaired Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041219&HITNO=14&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041219&THISHREF=http://c.moreover.com/click/here.pl%3fz2539038323%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041219&HITNO=14&MSIZE=989&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Oculocerebrorenal_Syndrome&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041219&THISHREF=http://c.moreover.com/click/here.pl%3fz2539038323%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: